MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Progenics Pharmaceuticals Company Profile (NASDAQ:PGNX)

Consensus Ratings for Progenics Pharmaceuticals (NASDAQ:PGNX) (?)
Ratings Breakdown: 4 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $10.75 (139.96% upside)

Analysts' Ratings History for Progenics Pharmaceuticals (NASDAQ:PGNX)
Show:
DateFirmActionRatingPrice TargetActions
6/15/2016Brean CapitalReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/10/2016Jefferies GroupReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/4/2016Needham & Company LLCReiterated RatingBuy$11.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/15/2016BTIG ResearchLower Price TargetBuy$12.00 -> $9.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/25/2014 forward)
Earnings History for Progenics Pharmaceuticals (NASDAQ:PGNX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/4/2016        
5/5/2016Q116($0.13)($0.18)$3.27 million$2.50 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/11/2016Q415($0.14)($0.10)$2.25 million$5.10 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/9/2015Q315($0.13)($0.14)$2.35 million$1.40 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/6/2015Q215($0.15)($0.17)$1.63 million$1.90 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/6/2015Q115($0.16)($0.15)$1.30 million$0.25 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/16/2015Q414($0.13)($0.18)$2.87 million($0.57) millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/7/2014Q314($0.16)$0.51$2.50 million$41.66 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/8/2014Q214($0.14)($0.17)$2.83 million$1.50 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/9/2014Q114($0.15)($0.15)$2.88 million$1.80 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/13/2014Q4($0.19)($0.14)$1.48 million$3.00 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/11/2013Q313($0.22)($0.17)$2.00 million$0.90 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/9/2013Q2 2013($0.24)($0.24)$1.86 million$1.80 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/10/2013Q1 2013($0.19)($0.22)$1.71 million$2.23 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/15/2013Q4 2012($0.31)($0.01)$1.16 million$8.87 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/8/2012Q312($0.30)($0.33)$2.52 million$1.10 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/9/2012($0.32)($0.32)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/8/2012($0.33)($0.39)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/9/2011($0.33)($0.34)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/9/2011($0.25)$1.64ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/10/2011($0.51)($0.69)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/15/2011($0.57)($0.57)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Progenics Pharmaceuticals (NASDAQ:PGNX)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.12)($0.12)($0.12)
Q2 20161($0.11)($0.11)($0.11)
Q3 20161$0.52$0.52$0.52
Q4 20161($0.14)($0.14)($0.14)
(Data provided by Zacks Investment Research)
Dividend History for Progenics Pharmaceuticals (NASDAQ:PGNX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Progenics Pharmaceuticals (NASDAQ:PGNX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
6/11/2015Robert J IsraelEVPSell2,000$6.83$13,660.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/13/2015Robert J IsraelEVPSell3,000$7.00$21,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/11/2015Robert J IsraelEVPSell2,000$6.83$13,660.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/3/2015Robert J IsraelEVPSell5,000$6.49$32,450.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/12/2015Robert J IsraelEVPSell2,000$7.06$14,120.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/11/2014Robert J IsraelEVPSell3,000$7.07$21,210.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/21/2014Robert J IsraelEVPSell9,000$7.00$63,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/13/2014Robert J IsraelEVPSell10,000$6.83$68,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/11/2014Robert J IsraelEVPSell5,000$6.53$32,650.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/21/2014Healthcare Master Fun BroadfinMajor ShareholderBuy1,625,436$4.60$7,477,005.60View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/18/2014Healthcare Master Fun BroadfinMajor ShareholderBuy388,200$4.73$1,836,186.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/17/2014Healthcare Master Fun BroadfinMajor ShareholderBuy436,884$4.48$1,957,240.32View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/16/2014Healthcare Master Fun BroadfinMajor ShareholderBuy411,693$4.48$1,844,384.64View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/18/2013Robert J IsraelVPSell5,000$6.33$31,650.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/27/2013Mark Robert BakerCEOBuy1,262$2.72$3,432.64View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/22/2013Mark Robert BakerCEOBuy1,215$2.82$3,426.30View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/26/2012Mark Robert BakerCEOBuy1,142$3.01$3,437.42View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/28/2012Mark Robert BakerCEOBuy1,607$2.13$3,422.91View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/19/2012Mark Robert BakerCEOBuy11,800$1.96$23,128.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/16/2012Mark Robert BakerCEOBuy49,793$1.82$90,623.26View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/15/2012Mark Robert BakerCEOBuy48,833$1.69$82,527.77View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/24/2012Mark Robert BakerCEOBuy1,162$2.96$3,439.52View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/26/2012Mark Robert BakerCEOBuy1,036$3.32$3,439.52View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Progenics Pharmaceuticals (NASDAQ:PGNX)
DateHeadline
06/23/16 06:24 PMProgenics Pharmaceuticals Inc. (NASDAQ:PGNX) Current Analyst Ratings - Fiscal Standard
06/22/16 10:33 AMFirst Week of February 2017 Options Trading For Progenics Pharmaceuticals (PGNX)
06/21/16 05:24 PMProgenics Pharmaceuticals, Inc. Signs Commercial License Agreement with Selexis SA for Use of Proprietary Cell Line ... - Business Wire (press release)
06/21/16 05:24 PMProgenics Pharmaceuticals, Inc. (NASDAQ:PGNX) Stock Momentum Hits Weakness - CML News
06/21/16 10:11 AMProgenics Pharmaceuticals, Inc. Signs Commercial License Agreement with Selexis SA for Use of Proprietary Cell Line and SUREtechnology Platform
06/20/16 07:24 AMProgenics Pharmaceuticals Inc. (NASDAQ:PGNX) Analyst Price Targets For The Coming Week - Fiscal Standard
06/13/16 08:45 AMProgenics Pharma (PGNX) Will Present 1404 and PyL Data at SNMMI 2016 - StreetInsider.com
06/13/16 07:09 AMProgenics Pharmaceuticals Announces Presentations on its Prostate Cancer Imaging Programs at SNMMI 2016 - [at noodls] - June 13, 2016 TARRYTOWN, N.Y., June 13, 2016 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) announced today that data from its 1404 and PyL prostate cancer imaging programs will be presented ...
06/10/16 06:04 PMWill Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) Surprise Analysts? - Investor Newswire
06/09/16 03:16 PMPROGENICS PHARMACEUTICALS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
06/09/16 07:19 AMBradley Campbell, President and COO of Amicus Therapeutics, elected to Progenics Board of Directors - [at noodls] - June 9, 2016 TARRYTOWN, N.Y., June 09, 2016 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative medicines and other products for targeting and treating ...
06/08/16 08:51 AMStocks within Investors Screening: Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) , Progenics Pharmaceuticals Inc ... - Street Updates
06/08/16 08:51 AMPROGENICS PHARMACEUTICALS INC. (NASDAQ:PGNX) Financial Condition Compared to S&P 500 - CML News
06/08/16 07:23 AMProgenics Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : PGNX-US : June 8, 2016 -
06/07/16 08:34 AMTop Earnings to Watch for: Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) - iStreetWire
06/06/16 05:46 PMEarnings Stocks Analysis: Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), Total System Services, Inc. (NYSE:TSS) - Beacon Chronicle
06/06/16 09:32 AMHow Many Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX)'s Analysts Are Bearish? - HNN
06/06/16 09:32 AMSnapshot of Recent Traded Stocks: Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) , Sunesis Pharmaceuticals, Inc ... - Street Updates
06/03/16 08:42 AMProgenics Pharmaceuticals Inc. (NASDAQ:PGNX) Quarterly EPS Estimate At $0.54 - Investor Newswire - Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) Quarterly EPS Estimate At $0.54Investor NewswireFirst Call stated that Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) can touch $10.75 in coming one year. For the next quarter, the per-share earnings target is $0.54 and for ongoing fiscal at $0.12. EPS target for next year is $-0.33 versus the mean ...and more »
06/02/16 06:13 PMProgenics Pharmaceuticals to Present at the Jefferies 2016 Healthcare Conference - GlobeNewswire (press release) - Progenics Pharmaceuticals to Present at the Jefferies 2016 Healthcare ConferenceGlobeNewswire (press release)TARRYTOWN, N.Y., June 02, 2016 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc., (Nasdaq:PGNX), an oncology company focused on developing innovative medicines and other products for targeting and treating cancer, announced today that ...
06/02/16 08:48 AMProgenics Pharmaceuticals, Inc.'s Trend Down, Especially After Today's Weak Session - HNN - Progenics Pharmaceuticals, Inc.'s Trend Down, Especially After Today's Weak SessionHNNThe stock of Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) is a huge mover today! The stock decreased 1.89% or $0.1 during the last trading session, hitting $4.93. About 1.08 million shares traded hands or 38.15% up from the average. Progenics ...
06/02/16 08:48 AMNotable Stocks within Investor Radar Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) , Quest Diagnostics ... - Street Updates - Notable Stocks within Investor Radar Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) , Quest Diagnostics ...Street UpdatesOn 6/1/2016, Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) highlighted downward shift of -1.89% or -0.10 points to $4.93. The company traded a volume of 1.08 million shares over average volume of 888.64 thousand shares. Trailing twelve month period, ...and more »
06/02/16 07:45 AMProgenics Pharmaceuticals to Present at the Jefferies 2016 Healthcare Conference - [at noodls] - June 2, 2016 TARRYTOWN, N.Y., June 02, 2016 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc., (Nasdaq:PGNX), an oncology company focused on developing innovative medicines and other products for targeting ...
05/31/16 06:04 PMBroker Outlook For The Week Ahead: Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) - Share Trading News - Broker Outlook For The Week Ahead: Progenics Pharmaceuticals Inc. (NASDAQ:PGNX)Share Trading NewsProgenics Pharmaceuticals, Inc. is engaged in developing medicines and other products for targeting and treating cancer. The Company's products in development include therapeutic agents designed to target cancer and imaging agents, which focuses on ...
05/25/16 10:35 PMUpcoming Earnings Report: Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) - iStreetWire - Upcoming Earnings Report: Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX)iStreetWireProgenics Pharmaceuticals, Inc. (PGNX) retreated -0.2% to reach at the floor price of $4.89 as the company is set to share its next quarterly earnings on August 04, 2016. PGNX stock trades between $4.86 and $5.01 before the earnings release. Let's take ...Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) Updated Broker Price TargetsShare Trading Newsall 3 news articles »
05/25/16 08:43 AMStocks inside Investors Limelight: Becton, Dickinson and Company (NYSE:BDX) , Progenics Pharmaceuticals Inc ... - Street Updates - Stocks inside Investors Limelight: Becton, Dickinson and Company (NYSE:BDX) , Progenics Pharmaceuticals Inc ...Street UpdatesProgenics Pharmaceuticals Inc. (NASDAQ:PGNX) after beginning at $4.97, closed at $4.89 by cutting down -0.20% in recent trading session. Most recent session's volume of 709.94 thousand shares lower than its average volume of 890.31 thousand shares.and more »
05/23/16 10:25 AMHow Analysts Rated Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) Last Week? - Wall Street Hints and News - How Analysts Rated Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) Last Week?Wall Street Hints and NewsOut of 4 analysts covering Progenics Pharm (NASDAQ:PGNX), 0 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means NaN are positive. Progenics Pharm has been the topic of 4 analyst reports since August 6, 2015 according to StockzIntelligence Inc. Below ...After Last Week What Do Analysts Think Of Progenics Pharmaceuticals Inc. (NASDAQ:PGNX)Share Trading Newsall 2 news articles »
05/23/16 07:29 AMProgenics Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : PGNX-US : May 23, 2016 -
05/22/16 10:02 AMAlpha One Assigns Impact Score Of 76 To Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) - RealistInvestor.com - Alpha One Assigns Impact Score Of 76 To Progenics Pharmaceuticals Inc. (NASDAQ:PGNX)RealistInvestor.comAlpha One analyzed the various web articles published on Progenics Pharmaceuticals Inc. (NASDAQ:PGNX), and thereafter it gave company a daily sentiment score of 0.31. The entity designs algorithm based assessment to known stock sentiment on stock ...and more »
05/19/16 05:31 PMRevenue Update on Progenics Pharmaceuticals(NASDAQ:PGNX) - Trade Calls - Revenue Update on Progenics Pharmaceuticals(NASDAQ:PGNX)Trade CallsProgenics Pharmaceuticals(NASDAQ:PGNX) announced the earnings results for Fiscal Year 2016 and Q1. The results came in during Pre-market on May 5, 2016. Company reported revenue of $2.45M. Analysts estimated a revenue of $3.27M. Earnings per ...
05/19/16 08:47 AMYesterday Trading Recap: Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) , Clovis Oncology, Inc. (NASDAQ:CLVS) - Street Updates - Yesterday Trading Recap: Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) , Clovis Oncology, Inc. (NASDAQ:CLVS)Street UpdatesOn 5/18/2016, shares of Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) rose +2.80% in trading session and finally closed at $4.78. The company most recent volume stood at 512.21 thousand shares as compared to its average volume of 900.97 thousand ...and more »
05/18/16 11:16 AMProgenics Pharmaceuticals, Inc. :PGNX-US: Earnings Analysis: Q1, 2016 By the Numbers -
05/17/16 10:28 PMDon't Miss: Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), Ocular Therapeutix, Inc. (NASDAQ:OCUL), Sandridge ... - KC Register - Don't Miss: Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), Ocular Therapeutix, Inc. (NASDAQ:OCUL), Sandridge ...KC RegisterProgenics Pharmaceuticals, Inc. (NASDAQ:PGNX) announced financial and business results for the first quarter 2016. First quarter revenue totaled $2.5 million, up from $0.2 million in the 2015 period, reflecting RELISTOR royalty income of $2.2 million ...
05/17/16 05:20 PMProgenics Pharma Incorporated (NASDAQ:PGNX) Sellers Covered 1.75% of Their Shorts - Wall Street Hints and News - Progenics Pharma Incorporated (NASDAQ:PGNX) Sellers Covered 1.75% of Their ShortsWall Street Hints and NewsThe stock of Progenics Pharma Incorporated (NASDAQ:PGNX) registered a decrease of 1.75% in short interest. PGNX's total short interest was 8.63M shares in May as published by FINRA. Its down 1.75% from 8.79M shares, reported previously.
05/16/16 05:12 PMTrading Overview of Two Stocks: Hooper Holmes, Inc. (NYSEMKT:HH) , Progenics Pharmaceuticals Inc. (NASDAQ ... - Street Updates - Trading Overview of Two Stocks: Hooper Holmes, Inc. (NYSEMKT:HH) , Progenics Pharmaceuticals Inc. (NASDAQ ...Street UpdatesProgenics Pharmaceuticals Inc. (NASDAQ:PGNX) moved in green zone with rise of +0.01 points or +0.22% to $4.64. The company has a market worth of $324.55M.Total 585.64 thousand shares were exchanged in last trading session as opposed to average ...Were Analysts Bearish Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) This Week?Wall Street Hints and NewsProgenics Pharmaceuticals Inc. (NASDAQ:PGNX) Latest Impact Score At 76RealistInvestor.comAfter Last Week What Do Analysts Think Of Progenics Pharmaceuticals Inc. (NASDAQ:PGNX)Share Trading Newsall 4 news articles »
05/16/16 03:18 PMETF’s with exposure to Progenics Pharmaceuticals, Inc. : May 16, 2016 -
05/16/16 10:26 AMWere Analysts Bearish Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) This Week? - Wall Street Hints and News - Were Analysts Bearish Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) This Week?Wall Street Hints and NewsOut of 4 analysts covering Progenics Pharm (NASDAQ:PGNX), 4 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Progenics Pharm has been the topic of 4 analyst reports since August 6, 2015 according to StockzIntelligence Inc. Below ...Trading Overview of Two Stocks: Hooper Holmes, Inc. (NYSEMKT:HH) , Progenics Pharmaceuticals Inc. (NASDAQ ...Street UpdatesProgenics Pharmaceuticals Inc. (NASDAQ:PGNX) Latest Impact Score At 76RealistInvestor.comAfter Last Week What Do Analysts Think Of Progenics Pharmaceuticals Inc. (NASDAQ:PGNX)Share Trading Newsall 4 news articles »
05/15/16 05:55 PMProgenics Pharmaceuticals Inc. (NASDAQ:PGNX) Latest Impact Score At 76 - RealistInvestor.com - Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) Latest Impact Score At 76RealistInvestor.comProgenics Pharmaceuticals Inc. (NASDAQ:PGNX) has a 0 daily sentiment score given by Alpha One after scanning articles on various online news platform. Alpha One performs algorithm based analysis to reach stock sentiment based on content published ...After Last Week What Do Analysts Think Of Progenics Pharmaceuticals Inc. (NASDAQ:PGNX)Share Trading Newsall 5 news articles »
05/13/16 05:45 PMProgenics Pharmaceuticals Inc. (NASDAQ:PGNX) Updated Broker Price Targets - Share Trading News - Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) Updated Broker Price TargetsShare Trading NewsMarket analysts have recently updated their ratings and price targets on shares of Progenics Pharmaceuticals Inc. (NASDAQ:PGNX). The latest reports which are currently in issue on Friday 13th of May state 0 analysts have a rating of “strong buy”, 0 ...and more »
05/13/16 12:04 PMPROGENICS PHARMACEUTICALS INC Financials -
05/13/16 07:18 AMProgenics Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : PGNX-US : May 13, 2016 -
05/12/16 10:57 PMProgenics Pharmaceuticals Inc. (PGNX) Drops 5.58% on May 11 - Equities.com - Progenics Pharmaceuticals Inc. (PGNX) Drops 5.58% on May 11Equities.comProgenics Pharmaceuticals Inc. (PGNX) was one of the Russell 2000's biggest losers for Wednesday May 11 as the stock slid 5.58% to $4.74, a loss of $-0.28 per share. Starting at an opening price of $5.00 a share, the stock traded between $4.72 and $5 ...
05/12/16 05:49 PMAnalytical Report of the Stock: Progenics Pharmaceuticals (PGNX) - News Oracle - Analytical Report of the Stock: Progenics Pharmaceuticals (PGNX)News OracleLast Trade: The Company fell -5.58% and finished at $4.74. The daily volume was measured at 857,816.00 shares. The 52-week high of the share price is $11.15 and the 52-week low is $3.61. The company has a market cap of $326.34 million. Its latest ...and more »
05/12/16 04:13 AMHow Analysts Rated Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) Last Week? - B.O.D.Y Confidential - How Analysts Rated Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) Last Week?B.O.D.Y ConfidentialOut of 4 analysts covering Progenics Pharm (NASDAQ:PGNX), 4 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Progenics Pharm has been the topic of 4 analyst reports since August 6, 2015 according to StockzIntelligence Inc. Below ...
05/08/16 11:02 PMProgenics Pharmaceuticals Inc. (NASDAQ:PGNX) Broker Price Targets For The Coming Week - Share Trading News - Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) Broker Price Targets For The Coming WeekShare Trading NewsMarket analysts have recently updated their ratings and price targets on shares of Progenics Pharmaceuticals Inc. (NASDAQ:PGNX). The latest reports which are currently in issue on Sunday 8th of May state 0 analysts have a rating of “strong buy”, 0 ...and more »
05/08/16 11:02 PMFY2019 EPS Estimates for Progenics Pharmaceuticals, Inc. Reduced by Jefferies Group (PGNX) - Washington News Wire - Washington News WireFY2019 EPS Estimates for Progenics Pharmaceuticals, Inc. Reduced by Jefferies Group (PGNX)Washington News WireProgenics Pharmaceuticals logo Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) – Jefferies Group decreased their FY2019 EPS estimates for shares of Progenics Pharmaceuticals in a research note issued to investors on Thursday, according to Zacks ...
05/06/16 04:21 AMProgenics Pharmaceuticals : reports 1Q loss - TARRYTOWN, N.Y. (AP) _ Progenics Pharmaceuticals Inc. (PGNX) on Thursday reported a loss of $12.7 million in its first quarter. The Tarrytown, New York-based company said it had a loss of 18 cents per share. The biopharmaceutical company posted revenue of ...
05/05/16 06:02 PMTwo Buzzers to Observe: Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) , Diplomat Pharmacy, Inc. (NYSE:DPLO) - Street Updates - Two Buzzers to Observe: Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) , Diplomat Pharmacy, Inc. (NYSE:DPLO)Street UpdatesProgenics Pharmaceuticals, Inc. (PGNX) recently declared that it has granted an exclusive license to Bayer for the development and commercialization of therapeutic antibodies combining the Company's prostate specific membrane antigen (PSMA) antibody ...
05/05/16 07:07 AMPROGENICS PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements -
05/05/16 06:41 AMProgenics Pharmaceuticals Announces First Quarter 2016 Financial and Business Results - [at noodls] - May 5, 2016 On May 2nd, the Company Announced It Had Granted Exclusive World-Wide Rights to Bayer to Develop and Commercialize Products Using Progenics' PSMA Antibody Technology In Combination with Alpha-Emitting ...
About Progenics Pharmaceuticals

Progenics Pharmaceuticals logoProgenics Pharmaceuticals, Inc. is engaged in developing medicines and other products for targeting and treating cancer. The Company's products in development include therapeutic agents designed to target cancer and imaging agents, which focuses on enabling clinicians and patients to accurately visualize and manage their diseases. The Company's EXINI Bone BSI is an analytical tool that employs an artificial intelligence-based approach to apply techniques of statistical analysis and pattern recognition to quantify the information produced by bone scintigraphy (bone scan) images used to view cancer present in the skeleton. The EXINI Bone BSI tool reads bone scans and produces an automated Bone Scan Index quantification. The Company's clinical-stage products include AZEDRA, 1404 (trofolastat), PyL ([18F] DCFPyL), 1095 and PSMA ADC. The Company's partnered products include Relistor-Subcutaneous injection, Relistor-Oral Tablets and PRO 140.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: PGNX
  • CUSIP: 74318710
Key Metrics:
  • Previous Close: $4.48
  • 50 Day Moving Average: $4.81
  • 200 Day Moving Average: $4.84
  • P/E Ratio: N/A
  • P/E Growth: 0.13
  • Market Cap: $313.36M
  • Current Quarter EPS Consensus Estimate: $0.12 EPS
Additional Links:
Progenics Pharmaceuticals (NASDAQ:PGNX) Chart for Saturday, June, 25, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha